Federal Circuit Reinstates Novartis Patent for Heart Drug, Entresto, Affecting Generic Market Entry

In a notable decision for the pharmaceutical industry, the Federal Circuit on Friday reinstated a patent for Entresto, a widely-used heart failure medication produced by Novartis. This development is part of multidistrict litigation where Novartis has sought to prevent the entry of generic versions of the drug into the market. The revival of this patent is crucial for Novartis in maintaining its market position against generic competitors. Legal professionals and pharmaceutical stakeholders can follow the ongoing proceedings and nuances of this case by accessing the detailed report on Law360.